IP Library › Granted Patent US 7,332,161
Granted Patent B2
US 7,332,161 · App. 11/343,003 · Granted Feb 19, 2008

Treatment of disease with antibodies against high molecular weight kininogen domain 5

Assignees: Temple University - Of The Commonwealth System of Higher Education; Bristol-Myers Squibb Pharma Company
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,332,161
App. No.
11/343,003
Granted
Feb 19, 2008
Kind
B2
Abstract

Antibodies directed against an antigenic determinant of high molecular weight kininogen domain 5, particularly a determinant located in the region formed by light chain amino acids Gly(440) to Lys(502), inhibit angiogenesis.

Claims (5)

1. A method for treating rheumatoid arthritis comprising administering to a mammal an effective amount of an antibody against an antigenic determinant of high molecular weight kininogen domain 5, wherein the antibody binds to an antigenic determinant which is recognized by the antibody product of hybridoma ATCC HB-8964.

2. The method according to claim 1 wherein the antibody is a monoclonal antibody.

3. The method according to claim 1 , wherein the antibody comprises the antibody product of hybridoma ATCC HB-8964.

4. The method according to claim 1 , wherein the antibody is a chimeric antibody.

5. The method according to claim 1 , wherein the antibody is a humanized antibody.

Continuity (3)
Continuation 1012994600
Provisional Application 6016516500 · Nov 12, 1999
Related Publication 20060115471A1 · Jun 1, 2006